CompletedPhase 4

Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection

Iran400 participantsStarted 2007-03

Plain-language summary

Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection. We are trying the PEGASYS plus Ribavirin in Hemophilic patients with HCV.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HCV RNA positive * Age older than 12 years Exclusion Criteria: * Ongoing pregnancy or breast feeding * Hx of HCC * Hx of alcoholic liver disease * Hx of bleeding from esophageal varices * Hx of hemochromatosis * Hx of autoimmune hepatitis * Hx of Suicidal attempt * Hx of cerebrovascular dis * Hx of severe retinopathy * Hx of severe psoriasis * Hx of scleroderma * Hx of metabolic liver disease * Hx of SLE

What they're measuring

Early Virologic Response

Timeframe: After 12 weeks of Treatment

End of Treatment Response

Timeframe: 24 weeks for : Genotype 2 & 3; 48 Weeks for other genotype

Sustained Virologic Response

Timeframe: 24 weeks after Treatment

Rapid Virologic Response

Timeframe: One month after Treatment

Trial details

NCT IDNCT00707772

SponsorBaqiyatallah Medical Sciences University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-09

View on ClinicalTrials.gov More Hepatitis C trials